MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Core Insights - MetaVia Inc. has initiated the first patient dosing in the 8-week 48 mg multiple ascending dose (MAD) cohort of its Phase 1 clinical trial for DA-1726, targeting obesity, with top-line data expected in Q4 2025 [1][2] - The company has signed a collaboration with Syntekabio to explore additional indications for DA-1241 beyond Metabolic Dysfunction-Associated Steatohepatitis (MASH) [1][5] - As of the end of Q2 2025, MetaVia reported $17.6 million in cash, which is anticipated to fund operations into 2026 [1][6] Clinical Development - DA-1726 is a dual agonist targeting GLP1R and GCGR, showing promising results in previous cohorts with an average weight loss of 4.3% and a maximum of 6.3% at the 32 mg dose [2][4] - The 48 mg cohort aims to evaluate longer-term efficacy and safety, building on the favorable safety profile observed in earlier trials [2][3] - DA-1241 has shown potential in reducing liver fat and inflammation when combined with an FGF21 analogue, with ongoing efforts to schedule an end-of-Phase 2 meeting with the FDA [2][5] Financial Performance - R&D expenses for Q2 2025 were approximately $2.3 million, a significant decrease from $8.1 million in Q2 2024, primarily due to lower direct expenses related to both DA-1241 and DA-1726 [4][6] - The net loss for Q2 2025 was $4.0 million, or $0.26 per share, compared to a net loss of $10.1 million, or $1.85 per share, in Q2 2024 [6][12] - Total operating expenses for Q2 2025 were approximately $4.3 million, down from $10.1 million in the same period last year, reflecting reduced R&D spending [6][12] Strategic Collaborations - The collaboration with Syntekabio aims to leverage AI for identifying new indications for DA-1241, enhancing its therapeutic profile [2][5] - MetaVia's partnership with Dong-A ST has facilitated funding and development efforts, with a recent private placement raising $10 million [5][6] Company Overview - MetaVia Inc. focuses on developing innovative therapies for cardiometabolic diseases, with DA-1726 and DA-1241 as its lead candidates [7]